FDA Approves Marijuana-Based CBD Drug for Epilepsy

Our take: First time the FDA has greenlighted a marijuana-derived drug... | ------------

The Food and Drug Administration (FDA) made history on Monday: For the first time, it approved the use of a marijuana-derived drug.

The drug, Epidiolex, treats two rare and severe forms of epilepsy in patients ages 2 and older using a purified form of cannabidiol oil (CBD oil), a derivative of cannabis that doesn't result in a high.

GW Pharmaceuticals is producing the drug.

In clinical trials, it reduced seizures in people with Dravet syndrome and Lennox-Gastaut syndrome without the harsh side effects of typical epilepsy drugs, which can include nausea, blurred vision and liver problems.

In a press release, FDA Commissioner Scott Gottlieb, MD, makes clear this is not a sweeping legalization of marijuana in general, or any of its other 80 active chemicals:

Proponents of CBD oil say it brings including better sleep, pain management, and depression relief.

But the number of people who swear by it aside, CBD oil is classified as a Schedule I drug by the Drug Enforcement Administration (DEA), which means it has no medicinal value.

Read the rest of this story from prevention.com...

thumbnail courtesy of prevention.com

Want the the best stuff from our resource library delivered straight to your inbox?
We respect your privacy. That means no spam, ever.